Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics

Sepsis Clinical Trial

— DigiSep  

Official title:

Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04571801
• Other study ID #: DigiSep 01
• Status: Recruiting
• Phase: N/A
• Start date: March 16, 2022
• Est. completion date: August 31, 2024

Study information

• Verified date: March 2022
• Source: University Hospital, Essen
• Contact: Thorsten Brenner, MD
• Phone: +49 201 723
• Email: thorsten.brenner[@]uk-essen.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sepsis is triggered by an infection and represents one of the greatest challenges of modern intensive care medicine. With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. Culture-independent molecular diagnostic procedures may represent a promising alternative. In particular, the concept of plasmatic detection of circulating, free DNA employing next-generation sequencing (NGS) has shown to be suitable for the detection of disease-causing pathogens in patients with bloodstream infections.

The DigiSep-Trial is a randomized, controlled, interventional, multicenter trial to characterize the effect of the combination of NGS-based digital precision diagnostics, standard-of-care microbiological analyses and optional expert exchanges compared to solely standard-of-care microbiological analyses in the clinical picture of sepsis / septic shock. The study examines in 410 patients (n = 205 per arm) with sepsis / septic shock whether the so-called DOOR-RADAR (Desirability of Outcome Ranking / Response Adjusted for Duration of Antibiotic Risk) score (representing a combined endpoint including the criteria (1) inpatient admission time, (2) consumption of antibiotics, (3) mortality and (4) acute renal failure (ARF)) can be significantly improved, by application of an additional NGS-based diagnostic concept. We also aim to investigate whether the new diagnostic procedure is cost-effective. It is postulated that the inpatient admission time, mortality rate, incidence of ARF, the duration of antimicrobial therapy as well as the costs of complications and outpatient aftercare can be reduced. Moreover, a significant improvement in the quality of life (QoL) of the affected patients can be expected.

Extensive preparatory work suggests that NGS-based diagnostics have higher specificity and sensitivity compared to standard-of-care microbiological analyses for detecting bloodstream infections. This preliminary work for the DigiSep-Trial with the help of an interventional study design provides the optimal basis to establish this new concept as part of the national standard based on the best possible evidence.

Description:

Sepsis is a disease which is triggered by an infection and represents one of the greatest challenges of modern intensive care medicine. With regard to targeted anti-microbial therapy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the gold standard for diagnosis, although numerous limitations characterize these. In this context, culture-independent molecular biological processes are an alternative. In particular, the concept of serum detection of circulating, free DNA employing next-generation sequencing (NGS) seems to represent a promising diagnostic procedure in patients with bloodstream infections. The applicant's extensive preparatory work suggests that NGS-based diagnostics using the SIQ score have higher specificity and sensitivity compared to traditional culture-based methods for detecting bloodstream infections. This preliminary work for the DigiSep trial with the help of interventional study design provides the optimal basis to establish this new concept as part of the national standard based on the best possible evidence. The DigiSep trial is intended to characterize the effect of the combination of digital precision diagnostics, expert exchange and culture-based standard diagnostics compared to a purely culture-based conventional diagnosis in the clinical picture of sepsis / septic shock. The study examines in 410 patients (n = 205 per arm) with sepsis / septic shock whether the so-called DOOR-RADAR score (Desirability of Outcome Ranking / Response Adjusted for Duration of Antibiotic Risk Score) can be significantly improved, by application of the NGS. We also aim to also study whether the new procedure is cost-effective. It is postulated that the inpatient admission time, mortality rate, incidence of acute renal failure (ARF), the duration of anti-microbial therapy as well as the costs of complications and outpatient aftercare can be reduced. Also, a significant improvement in the quality of life of the affected patients can be expected.

As part of the study, the essential data is collected once at the time of sepsis (= onset). The culture-based diagnostics include the guideline-oriented collection of 2 blood culture sets (2 x aerobic / 2 x anaerobic) to the onset and three days later. At the same time, serum samples are obtained for NGS-based pathogen diagnostics. Additional sampling for NGS-based diagnostics can be made up to day 14 after onset or whenever the attending physician establishes a clinical indication for the collection of further blood cultures. The aforementioned cultures vs NGS-based pathogen diagnostics are also accompanied by extended immunological monitoring from blood plasma samples as well as an NGS-based transcriptome analysis. The associated sampling takes place at the time of onset, 3, 7 and 14 days after the beginning of sepsis. Routine microbiological findings from other biological samples (e.g. surgical swabs, drainage secretions, tracheal secretions, tissue samples) are included in the evaluation if these were collected three days before or after the extraction of serum samples for NGS-based diagnostics. The clinical data collection is also carried out at the time of sepsis (= onset), 3, 7 and 14 days later, analogous to the above-mentioned sample collection. The final outcome evaluation takes place 28 days (= 28 d) after the onset of sepsis. The study-related burden on the individual study patient includes a total of 17 ml of whole blood for NGS-based diagnostics, the four samples of 7.5 ml of whole blood for immunological monitoring and the four samples of 2.7 ml of whole blood for transcriptome analysis. The minimum total volume, therefore, amounts to the collection of approximately 75 ml of whole blood within the first 14 days after the onset of sepsis. The sampling takes place with the collection of the blood cultures or within the framework of the daily routine blood samples so that no further venous punctures are required here. Infection parameters such as procalcitonin (PCT) are carried out within the framework of daily regular blood collection and therefore, do not require any additional vascular punctures. The same principle applies to the collection of blood cultures which are routinely obtained as part of standard diagnostics in patients with suspected or proven sepsis. The required blood samples of two 40 ml of whole blood (each two sets of 2 x aerobic / 2 x anaerobic = 4 x 10 ml = 40 ml) therefore do not represent any additional burden due to the study. A further additional burden for the patient concerning invasive procedures or examinations is not expected in the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 410
• Est. completion date: August 31, 2024
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients who develop sepsis or septic shock within < 24 h in accordance with the new sepsis definition (Sepsis-3) in the above-mentioned participating centers and consent to participation in the study will be included.

General inclusion criteria:

• Written consent by the study participant or a legally appointed representative

• Age >18 years

Sepsis:

• Life-threatening organ dysfunction due to a dysregulated immune response on the basis of a suspected or proven infection

• Detection of organ dysfunction indicated by SOFA score of = 2 points Alternative:

Change of the quick (q) SOFA score of 2 points as an indication of a sepsis

Or septic shock:

• Persistent hypotension despite adequate volume substitution, which necessitates the use of vasopressors, to maintain an arterial medium pressure of > 65 mmHg

• Serum lactate > 2 mmol/l (18 mg/dl)

Exclusion Criteria:

• Age < 18 years

• Refusal to participate in the study

• Probable discharge of the patient from the intensive care unit within the first 72 h of initial study inclusion

• Palliative therapy approach

• Death of the patient is already foreseeable or inevitable at trial inclusion

• Patients who have already been included in the study but require re-admission to the intensive care unit cannot be included a second

Related Conditions & MeSH terms

• Sepsis
• Septic Shock
• Toxemia

Intervention

Diagnostic Test:
• Standard diagnostics
Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
• Next Generation Sequencing (NGS)
Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock

Locations

Country	Name	City	State
Germany	University Hospital Aachen	Aachen	Nordrhein-Westfalen
Germany	University Hospital Charité	Berlin
Germany	Klinik Evangelisches Krankenhaus Bethel gGmbH Bielefeld	Bielefeld	Nordrhein-Westfalen
Germany	University Hospital Bonn	Bonn	Nordrhein-Westfalen
Germany	University Hospital Düsseldorf	Düsseldorf	Nordrhein-Westfalen
Germany	University Hospital Essen	Essen	Nordrhein-Westfalen
Germany	University Hospital Frankfurt	Frankfurt	Hessen
Germany	University Hospital Göttingen	Göttingen	Niedersachsen
Germany	University Hospital Hannover (MHH)	Hannover	Niedersachsen
Germany	University Hospital Heidelberg	Heidelberg	Baden-Württemberg
Germany	Heidenheim Hospital	Heidenheim	Baden-Württemberg
Germany	University Hospital Köln	Köln	Nordrhein-Westfalen
Germany	Konstanz Hospital	Konstanz	Baden-Württemberg
Germany	University Hospital Leipzig	Leipzig	Sachsen
Germany	Klinik Evangelisches Krankenhaus Luckau gGmbH	Luckau	Brandenburg
Germany	University Hospital TU München	München	Bayern
Germany	University Hospital Regensburg	Regensburg	Bayern
Germany	University Hospital Rostock	Rostock	Mecklenburg-Vorpommern
Germany	University Hospital Tübingen	Tübingen	Baden-Württemberg
Germany	University Hospital Ulm	Ulm	Baden-Württemberg
Germany	Helios Dr. Horst Schmidt Hospital	Wiesbaden	Hessen
Germany	University Hospital Würzburg	Würzburg	Bayern

Sponsors (11)

Lead Sponsor

Collaborator

University Hospital, Essen

AOK Health Insurance, Rheinland, Hamburg, Barmer Health Insurance, Germany, Center for Infectious Diseases and Infection Control, Jena University Hospital, Coordination Centre for Clinical Trials (KKS), University of Heidelberg, Department of Anesthesiology, Heidelberg University Hospital, Department of Infectious Diseases, University Hospital Essen, Health Economics and Health Care Management, Bielefeld University, Institute of Medical Biometry and Informatics, University of Heidelberg, Noscendo GmbH, Germany, Techniker Health Insurance, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Desirability of Outcome Ranking / Response Adjusted for Duration of Antibiotic Risk-Score	DOOR/RADAR-score [points], (min. 1, max. 5), a lower score indicates a better outcome	28 days
Secondary	Disease severity	Long term mortality [%]	at 90 and 180 days
Secondary	Disease severity	Hospital length of stay [days]	at 28, 90, and 180 days
Secondary	Degree of organ dysfunction/-failure	Duration of mechanical ventilation [days]	at 28, 90, and 180 days
Secondary	Degree of organ dysfunction/-failure	Length of time until shock resolution [hours]	during 28 days
Secondary	Degree of organ dysfunction/-failure	Ongoing need for renal replacement therapy [%]	at 28, 90, and 180 days
Secondary	Microbiological outcome	Cumulative need for anti-infective drugs [days]	at 28, 90, and 180 days
Secondary	Microbiological outcome	Beginning of a targeted anti-infective treatment regimen [days]	during 28 days
Secondary	Health economic outcome	Utilization of healthcare ressources (outpatient and inpatient) [Euro]	at 28, 90, and 180 days
Secondary	Health economic outcome	Policyholder costs (outpatient and inpatient) [Euro]	at 28, 90, and 180 days
Secondary	Economic outcome	Disease-related absence from work [days]	at 28, 90, and 180 days
Secondary	Quality-of-life (QoL) based on VR-36 questionnaire	VR-36 questionnaire [points] including 2 summary components, 8 scales, 36 items, a higher score indicates a higher Quality-of-Life (QoL)	90 and 180 days
Secondary	Quality-of-life (QoL) based on EQ-5D-5L questionnaire	EQ-5D-5L questionnaire [points] including 10 items, a higher score indicates a higher Quality-of-Life (QoL)	at 0, 90 and 180 days